New eye drop shows promise for Sjögren's dry eye relief
NCT ID NCT06520202
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase trial tested a new eye drop called rhPRG4 in 8 people with Sjögren's syndrome-related dry eye. Participants received either the active drop or a placebo, then switched after 90 minutes. The study measured eye dryness and safety over a single day. Because the trial was very small and terminated early, results are limited.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- rhPRG4 (recombinant human proteoglycan 4) eye drops
- What this could lead to
- If it works, this could point toward a new eye drop to temporarily relieve dryness and discomfort in people with Sjögren's syndrome.
- What could go wrong
- This is a very small, early-phase study (only 8 people) that was terminated, so results may be limited. The treatment only provides short-term relief and is not a cure.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SJOGREN'S SYNDROME WITH DRY EYE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Sydney Eye Hospital
Sydney, Australia